Veraxa Biotech AG

What they do

Veraxa Biotech AG is the listed public company (PubCo) formed from the combination of Veraxa Biotech AG and Voyager Acquisition Corp., a Cayman Islands SPAC. It operates as a pharmaceutical preparations company, with the combined entity's business being the pre-Closing Veraxa and its subsidiary. The filing is a Form 20-F for fiscal year ended December 31, 2025, submitted as a shell company report with the triggering event dated June 10, 2026. Its ordinary shares trade on Nasdaq under VRXA and warrants under VRXAW, exercisable at $11.50 per share.

Revenue drivers

• Pharmaceutical preparations (combined company business) — The filing classifies the registrant under SIC code 2834, Pharmaceutical Preparations, indicating the combined company's operations are in pharmaceutical products; the excerpts provided do not disclose specific product lines or revenue by segment.
• Pre-Closing Veraxa operations — The filing refers to 'Veraxa' as Veraxa Biotech AG and its subsidiary prior to the Closing, and the business of the combined company is that pre-Closing business; no product-level revenue breakdown is included in the provided excerpts.

Recent performance

The provided excerpts do not contain an MD&A results discussion or financial statements with revenue, net loss, or cash figures. The filing is a Form 20-F shell company report for the fiscal year ended December 31, 2025, with a triggering event date of June 10, 2026. As of June 10, 2026, the company reported 141,407,813 ordinary shares outstanding and 22,706,305 warrants to purchase ordinary shares. The registration statement lists ordinary shares on the Nasdaq Stock Market LLC and warrants on the Nasdaq Capital Market LLC. The document includes financial statement pages (Items 17 and 18) but the excerpted text does not include the actual financial results.

Strategy

The filing states that the combined public company resulted from the Closing of the Business Combination between Veraxa and Voyager Acquisition Corp. The forward-looking statement section references PubCo's mission, goals and strategies, future business development, financial condition and results of operations, and expectations regarding demand for and market acceptance of its products and services. It also cites expected growth of the cancer therapeutics and healthcare industry and PubCo's ability to grow market share. The provided excerpts do not include specific disclosed investment amounts, pipeline programs, or milestones.

Risks

• De-SPAC integration and structure risk — The company is newly formed from the Business Combination with Voyager Acquisition Corp., and the filing's forward-looking statements flag risk that the expected benefits of the Business Combination may not be realized as projected.
• Reliance on market acceptance of products — The filing's forward-looking statements specifically reference PubCo's expectations regarding demand for and market acceptance of its products and services, indicating dependence on commercial adoption.
• Industry competition — The forward-looking statements list competition in PubCo's industry as a stated risk area without disclosing specific competitors in the excerpts.
• Capital requirements and cash runway — The filing cites PubCo's future capital requirements and sources and uses of cash as a forward-looking risk area, consistent with a pharmaceutical company that may need additional financing.

Outlook

The provided excerpts do not contain a management outlook or guidance section. The forward-looking statement section indicates the company may address future business development, financial condition, results of operations, revenue, cost and expenditure expectations, and market share growth, but no specific projections are included in the text supplied. Management's actual outlook statements would appear in the full Item 5 Operating and Financial Review and Prospects, which is not included here.